Publications by authors named "Alessandro Di Federico"

Claim this Profile
D
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study.
Lingzhi Hong, Alessandro Di Federico, Bolun Liu, Alissa J Cooper, Joao V Alessi

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer.
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, Joao V Alessi, Alessandro Di Federico

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, Andrea De Giglio, Francesca Lo Bianco

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Alessandro Di Federico

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone metastases in NSCLC: Modern paradigms in management and supportive care.
Gabriele Minuti, Giorgia Pasqualini, Alice Avancini, Niccolò Giaj-Levra, Francesca Colonese, Alessandro Di Federico

Cancer Treat Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Federico Cappuzzo

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 and PD-1 Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.
Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder, Bijaya Sharma, Kristen Felt, Alessandro Di Federico

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.
Federica Pecci, Prashasti Agrawal, Jessica S Ross, Biagio Ricciuti, Seshiru Nakazawa, Alessandro Di Federico

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Alessandro Di Federico

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, Felix H Gottlieb, Francesco Facchinetti, Alessandro Di Federico

J Thorac Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci, Alessandro Di Federico, Federico Cappuzzo

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC.
Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Alessandro Di Federico

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upfront osimertinib and as sequential therapy in patients with -mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.
Edouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, Frank Aboubakar, Helena Gerber, Alessandro Di Federico

Transl Lung Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC.
Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, Biagio Ricciuti, Joao V Alessi, Alessandro Di Federico

J Thorac Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients.
Adriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, Teja Ganta, Thomas U Marron, Alessandro Di Federico

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Seshiru Nakazawa, Federica Pecci, Igor Odintsov, Dimitris Gazgalis, Felix H Gottlieb, Alessandro Di Federico

Cancer Discov· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
Federica Pecci, Rohit Thummalapalli, Stephanie L Alden, Biagio Ricciuti, Joao V Alessi, Alessandro Di Federico

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study.
Alice Avancini, Niccolò Giaj-Levra, Gabriele Minuti, Giorgia Pasqualini, Francesca Colonese, Alessandro Di Federico

Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.
Sara Stumpo, Andrea Carlini, Francesco Mantuano, Alessandro Di Federico, Barbara Melotti

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial.
Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, Laura Bonanno, Xiaoyue Wang, Alessandro Di Federico

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Alessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, Edoardo Garbo, David J Pinato, Alessandro Di Federico

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Maria Concetta Nigro, Andrea Marchetti, Elena Rosa Fumagalli, Ida De Luca, Alexia Francesca Bertuzzi, Alessandro Di Federico

JAMA Netw Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report.
Andrea De Giglio, Federico Zacchini, Giulia Venturi, Alessandro Di Federico, Claudia Parisi

J Liq Biopsy· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis